This work is licensed under the Creative Commons Attribution International License (CC BY)
Except for linagliptin, which is eliminated via the biliary route, all other DPP-4 inhibitors require dose adjustments in cases of moderate or severe renal failure, though this recommendation is made for pharmacokinetic reasons, not for reasons of safety
Brown label (1 mg) The brown-labeled pen delivers 1 mg of semaglutide in 0.5 mL
[DOI] [PubMed] [Google Scholar] 32.Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP
Supplemental Figure 7
Zepbound is also FDA-approved to treat sleep apnea in patients with obesity, while Wegovy is FDA-approved to treat cardiovascular disease